Current Month 2013
Article Features
  Acupuncture Improves Quality of Life for Breast Cancer Patients Using Aromatase Inhibitors
Cell's Recycling Center Implicated in Division Decisions
Cultured Circulating Tumor Cells Reveal Genetic Profile, Potential Drug Susceptibility of Breast Cancer Cells
Cyclin D, Long Believed to Promote Cancer, Actually Activates Tumor Suppressor
Exposure to Dim Light at Night May Make Breast Cancers Resistant to Tamoxifen
Gene Changes in Breast Cancer Cells Pinpointed with New Computational Method
How Antioxidants Can Accelerate Cancers, And Why They Don’t Protect Against Them
New Research Reveals How Cannabis Compound Could Slow Tumor Growth
New Tamoxifen Skin Gel Fights Breast Cancer Without Blood Clot Risk
Protein Pushes Breast Cancer Cells to Metastasize
Researchers Identify Possible Target for Immunotherapy in Early-Stage Breast Cancer
Researchers Recommend Updating the ‘Staging Criteria’ for Breast Cancer Diagnoses
Scientists Discover Genetic Cause of Common Breast Tumors in Women
Study Identifies Genes Linked to Breast Cancer in East Asian Women

Acupuncture Improves Quality of Life for Breast Cancer Patients Using Aromatase Inhibitors

Use of electroacupuncture (EA) – a form of acupuncture where a small electric current is passed between pairs of acupuncture needles – produces significant improvements in fatigue, anxiety and depression in as little as eight weeks for early stage breast cancer patients experiencing joint pain related to the use of aromatase inhibitors (AIs) to treat breast cancer. The results of a randomized, placebo-controlled trial examining the intervention led by researchers at the Perelman School of Medicine at the University of Pennsylvania are published in the journal Cancer. The study is the first demonstration of EA's efficacy for both joint pain relief, as well as these other common symptoms.

The results build upon earlier findings reported in November 2013, showing that EA can decrease the joint pain reported by roughly 50 percent of breast cancer patients taking AIs – the most-commonly prescribed medications to prevent disease recurrence among post-menopausal women with early-stage, hormone receptor positive breast cancer. Despite their efficacy, the joint pain associated with the use of AIs often leads to fatigue, anxiety, depression, and sleep disturbances for these patients, which researchers suggest may cause premature discontinuation of the drug. Previous studies have shown that nearly half of women taking AIs do not complete their recommended course of treatment, and that those who stop taking the drugs or don't take them as prescribed have a higher chance of dying of both breast cancer and other causes.

Read More of the Main Article

Visit the Ezine

Visit the BreastCenter

Visit the Quality Corner
Avon Breast Cancer Crusade - AVON the company for women

  This website is supported in part by an unrestricted educational grant provided by Avon